1672 — Ascletis Pharma Share News
0.000.00%
Last trade - 00:00- HK$10.63bn
- HK$8.44bn
- CNY2.03m
Brief: Ascletis Pharma Posts HY Loss Attributable Of RMB130.3 Mln
Brief: Ascletis Pharma Sees HY Net Loss Attributable RMB127.3 Million To RMB132.3 Million
Brief: Ascletis Pharma Post FY Revenue RMB56.6 Million Versus RMB54.1 Million
Brief: Ascletis Pharma Says To Repurchase Shares To Use Up To HK$200 Mln In Funds
Brief: Ascletis Pharma Receives China NMPA Approval Of A Phase IIa Clinical Trial For Asc10
Brief: Ascletis Pharma Says Co Remains Cautious On Rev Generated From Sale Of Ritonavir Tablets For FY23
Brief: Ascletis Pharma Inc Says FY Revenue RMB40.4 Million
Brief: Ascletis Pharma Says Group Has No Bank Account In Silicon Valley Bank
Brief: Ascletis Pharma Announces U.S. FDA Approval Of Conducting Phase IIa Clinical Trial For Asc10
Brief: Ascletis Pharma Says China's NMPA Approved IND Application Of Asc10 For Monkeypox Indication
Brief: Ascletis Announces Ind Approval Of Oral Viral Polymerase Inhibitor Asc10 For Monkeypox Indication By China Nmpa
Brief: Ascletis Pharma Announces A Supply Agreement Of Ritonavir Tablets With Simcere Pharmaceutical
Brief: Ascletis Pharma Updates On Study For Oral 3CLPRO Inhibitor ASC11 For COVID-19
China's Ascletis Pharma jumps most in 11 months on U.S. patent for product
Brief: Ascletis Announces Positive Phase I Clinical Results Of Oral Rdrp Inhibitor Asc10 For Covid-19
Brief: Ascletis Pharma Announces Positive Phase I Clinical Results Of Oral Rdrp Inhibitor Asc10 For Covid-19
Brief: Ascletis Pharma Announces Ind Approval Of Oral 3Clpro Inhibitor Asc11 For Covid-19
Brief: Ascletis Announces Completion Of 180 Patient Enrollment For Phase Ii Clinical Trial Of Fasn Inhibitor Asc40 For Acne
Brief: Ascletis Pharma Says Ind Filing Of Oral 3Clpro Inhibitor Asc11 Accepted By China Nmpa